证券之星消息，2月4日动物保健板块较上一交易日下跌0.95%，生物股份领跌。当日上证指数报收于 4102.2，上涨0.85%。深证成指报收于14156.27，上涨0.21%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920729 | 永顺生物 | 9.55 | 1.27% | 4.24万 | liv 4027.15万 | | 600195 | 中牧股份 | 8.00 | 1.14% | 13.94万 | + 1.11亿 | | 002688 | 金河生物 | 6.34 | 0.79% | 11.27万 | 7097.96万 | | 603566 | 普莱柯 | 14.09 | 0.64% | - 4.93万 | 6949.39万 | | 688526 | 科前生物 | 16.25 | 0.43% | 2.17万 | 3506.75万 | | 300119 | 瑞普生物 | 19.20 | 0.21% | 3.59万 | 6867.04万 | | 002141 ...

证券日报网讯 2月3日，生物股份发布公告称，持股5%以上股东内蒙古金宇生物控股有限公司所持 18600000股公司无限售流通股于2026年2月2日解除质押，占其持股14.82%。 （文章来源：证券日报） ...

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

金宇生物技术股份有限公司 关于股东股份解除质押的公告 证券代码：600201 证券简称：生物股份 公告编号：临 2026-003 生物控股原质押给西藏信托有限公司的本公司 18,600,000 股无限售流通股 股票已于 2026 年 2 月 2 日解除质押，并已办理完成上述股票解除质押的相关手续。 具体情况如下： | 股东名称 | 内蒙古金宇生物控股有限公司 | | --- | --- | | 本次解质（解冻）股份 | 18,600,000 股 | | 占其所持股份比例 | 14.82% | | 占公司总股本比例 | 1.67% | | 解质（解冻）时间 | 2026 年 2 月 2 日 | | 持股数量 | 125,510,800 股 | | 持股比例 | 11.29% | | 剩余被质押（被冻结）股份数量 | 15,820,000 股 | | --- | --- | | 剩余被质押（被冻结）股份数量占其所 | 12.60% | | 持股份比例 | | | 剩余被质押（被冻结）股份数量占公司 | 1.42% | | 总股本比例 | | 上述解除质押股份暂无后续质押计划。未来如有变动，公司将按照相关法律 法规 ...

生物股份公告，公司持股5%以上股东内蒙古金宇生物控股有限公司于2026年2月2日解除质押1860万 股，占其所持股份14.82%、占公司总股本1.67%；解除后持股1.26亿股，占11.29%；生物控股剩余质押 1582万股，占其所持股份12.60%、占公司总股本1.42%；生物控股及一致行动人合计持股1.55亿股，占 13.91%，累计质押1582万股，占合计持股10.23%。 ...

2026年02月02日，生物股份披露接待调研公告，公司于01月30日接待睿远基金、中信证券、天风证券、 国泰海通证券、招商证券、国投证券等28家机构调研。 生物股份（600201）最新股价为16.28元，较前一交易日收盘价下跌1.77元，跌幅为9.81%，总市值 180.99亿元。从行业市盈率来看，生物股份所处的农药兽药行业滚动市盈率平均47.77倍，行业中值 27.11倍，生物股份179.63倍排名第32位。 调研情况显示，生物股份非洲猪瘟疫苗临床试验进展顺利，于2025年7月取得临床批件，10月启动田间 试验，2026年1月23日完成首次攻毒试验并符合阶段性评价要求，计划4月上旬启动第二轮攻毒试验，6 月完成全部临床试验数据统计与分析。 公司非洲猪瘟疫苗具备显著竞争优势，包括高安全性和高保护性，采用保守性靶点设计对重组毒株、基 因二型毒株均具备较高交叉保护率，已包含完整的妊娠动物安全性实验数据；技术优势方面，公司拥有 大动物P3实验室，已建成专用GMP生产车间并通过验收，在产业化方面具备先发优势；时间壁垒明 显，是率先取得临床批件并完成首次攻毒试验的企业，已完成万头猪只大规模免疫实验。 参与此次调研的睿远 ...

证券之星消息，2月2日动物保健板块较上一交易日下跌4.9%，生物股份领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 3.98 | 0.76% | 29.51万 | 1.16亿 | | 002868 | *ST绿康 | 35.53 | -0.73% | 1.21万 | 4321.94万 | | 603566 | 普莱柯 | 13.72 | -1.15% | 7.48万 | 1.03亿 | | 688098 | 申联生物 | 9.36 | -1.78% | 4.23万 | 4019.07万 | | 688526 | 科前生物 | 15.98 | -3.33% | 4.70万 | 7617.62万 | | 600195 | 中牧股份 | 7.88 | -3.55% | 24.23万 | 1.95亿 | | 002688 | 金河生物 | ...

本报讯 （记者马宇薇）1月30日，金宇生物技术股份有限公司（以下简称"生物股份"）举办投资者接待 日，宣布其非洲猪瘟基因工程亚单位疫苗完成首轮临床试验攻毒验证，保护率达到评价标准。 自2018年非洲猪瘟疫情传入我国，给国内养猪产业带来了超万亿元的巨额经济损耗。鉴于该病毒结构繁 杂、具备强大的免疫逃逸能力，迄今为止，全球范围内尚未研发出安全可靠、可实现商业化应用的疫苗 产品。 2026年1月份，该疫苗首轮攻毒实验圆满结束。尤为关键的是，该疫苗采用基因工程亚单位技术，仅表 达8个保守抗原蛋白，不含活病毒，彻底杜绝了毒力返强风险。同时，其靶点在当前流行的重组毒株中 同源性高达99.7%。 依托高级别生物安全实验室（ABSL-P3）优势，生物股份建立了高通量分子筛选平台，完成了100多个 非洲猪瘟靶点蛋白的AI筛选与合成表达、攻毒验证，积累了大量数据，为未来应对新型毒株提供了坚 实的技术支撑。 生物股份董事长张翀宇表示，本阶段实验成功，聚集了政产学研资管用各部门融合创新的力量，更要感 谢监管部门对实验方案、过程提前介入、精心把关指导，对中国原创的重视、参与和支持。生物股份要 充分发挥好科技创新领军企业的作用，引领带动 ...

Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].